What Is Trulicity's Mechanism?
Trulicity (dulaglutide) is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1 (GLP-1), a hormone that boosts insulin release, slows gastric emptying, and reduces appetite to control blood sugar in type 2 diabetes.[1]
How Does It Differ from GIP Agonists?
Trulicity does not act on GIP (glucose-dependent insulinotropic polypeptide) receptors. Pure GIP agonists are rare in approved drugs; Trulicity lacks dual GLP-1/GIP activity, unlike newer options such as tirzepatide (Mounjaro), which targets both.[2]
Why the Confusion with Dual Agonists?
Patients and searches often mix up Trulicity with dual GLP-1/GIP drugs due to rising hype around weight loss benefits. Trulicity is GLP-1 only, approved for diabetes (not primary weight loss), with modest effects compared to dual agonists.[3]
Common Alternatives by Receptor Type
| Drug | Receptor Target | Primary Use |
|------|-----------------|-------------|
| Trulicity (dulaglutide) | GLP-1 only | Type 2 diabetes |
| Ozempic/Wegovy (semaglutide) | GLP-1 only | Diabetes/weight loss |
| Mounjaro/Zepbound (tirzepatide) | GLP-1 + GIP | Diabetes/weight loss |
| Lyxumia (lixisenatide) | GLP-1 only | Diabetes |
When Do Patents Expire for Trulicity?
Trulicity's main composition patent expires in 2029 in the US, with formulation patents extending to 2033. Challenges from generics are ongoing.4
[1]: FDA Label for Trulicity (https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125469s000lbl.pdf)
[2]: Eli Lilly Tirzepatide Mechanism (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tirzepatide-marketed-mounjaro-information)
[3]: NEJM Study on Dulaglutide (https://www.nejm.org/doi/full/10.1056/NEJMoa1901119)